Lucid Diagnostics Inc. (LUCD) Stock

Lucid Diagnostics Inc. (LUCD) is a Healthcare stock trading at $1.06 (as of 2026-06-18), with a market capitalization of $209.16M and a trailing P/E of -1.3. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Lucid Diagnostics Inc. is a commercial-stage medical diagnostics company focused on patients with gastroesophageal reflux disease and related risk of esophageal precancer and cancer. It develops diagnostic tools including the EsoGuard esophageal DNA test and the EsoCheck esophageal cell collection device, serving clinical and laboratory use; it is based in New York and is a subsidiary of PAVmed Inc.

Valuation — source: SEC EDGAR (first-party)
Price	$1.06
Market Cap	$209.16M
P/E Ratio	-1.3
EV / EBITDA	-3.7
Price / Book	52.29
Price / Sales	40.74
DCF Value (model)	$-4.30
DCF Upside vs Price	-505.7%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$4.71M
Net Margin	-1232.7%
Return on Equity	-1125.3%
Current Ratio	1.07
Revenue Growth (YoY)	51.7%
EPS Growth (YoY)	-67.3%
FCF Growth (YoY)	-1.9%

Financial Health — source: SEC EDGAR
Altman Z-Score	-9.35 (distress)

Valuation vs Sector & Industry
Stock P/E	-1.3
Sector P/E (Healthcare)	21.0
Industry P/E (Medical Equipment)	31.7
vs Sector	-106.4%
vs Industry	-104.2%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	VANGUARD GROUP INC ($5.42M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Medical Equipment
CEO	Lishan Aklog
Employees	72
Country	US
IPO Date	2021-10-14

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.